A COVID-19 vaccine is required to restore public confidence. Public confidence is required to kick start the global economy on its path to normal productivity levels. Similarly, the equity and credit markets will require public confidence and a healthy economy to return to sustainable growth. The COVID vaccine must be in production and readily available to meet demand in order to have the desired effect.
A readily available COVID-19 vaccine is what will be required to restore full public confidence. Public confidence is the key ingredient to help return the domestic and global economies to “normal” output levels. Readily available COVID testing is a step in the right direction but not enough. So where are we?
Johnson & Johnson (tkr: JNJ), stated that it expects to produce between 600-900 million vaccine doses by April 2021 if September trials have the desired outcome. We have highlighted the portion of J&J’s April 14th earnings call that covers the COVID 19 Vaccine Update in our YouTube video below: